Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
How to make nasi goreng – recipe | Felicity Cloake’s Masterclass
Flashback to 1965: Truman Capote and the Seaside Studio He Designed for Work
Sanctioned Russian vessel ablaze in Finnish waters after drone attack
ClearSpace Junk Removal Offers Easy Online Booking and Affordable Junk Removal in Atlanta
8 Best Travel Adapters (2026): 20+ Models Tested
New Orleans Guide: Where to Stay, Eat, Drink, and Revel in the Big Easy
Nscale slows hiring and curtails spending ahead of planned $35bn IPO
Best Black Friday Nintendo Switch 2 Deals (2026): Switch 2 Bundles and Games
This is how we do it: ‘One time my son said: “I heard you having sex. It was disgusting.” That killed the vibe’
Bitcoin briefly drops to $17K on Kraken, exchange upholds trades
Miley Cyrus marries Maxx Morando in California ceremony
Calls for Marilyn Manson performance to be pulled
South Korean exchanges halt CYBER transfers amid suspected bridge exploit
Advanced Global Manufacturing (AGM) Makes North American Debut at RE+ 26, Showcasing New Solar-Storage Technologies to Strong Reception
VTNODPL Launches Gold-Focused Trading Platform
Cruise.co.uk launches luxury cruise and stay itinerary marking Titanic’s legacy
Emirates opens experiential Travel Store in Cape Town
Vairnport Receives US$1.5 Million in SOL Market Incentives from SkyBridge Capital and the Solana Foundation
Author Slader Merriman Expands International Reach of Different with French and Spanish Editions
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.